Ozempic Breath Is on the Rise—and So Is This Unlikely Winner

Ozempic Breath Is on the Rise—and So Is This Unlikely Winner

Summary

Hershey’s CEO told stockholders that GLP-1 side effects are creating a ‘strong demand for gum.’

Original reporting

Open original source

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Related coverage